Other grades of this product :
| Bendamustine Basic information |
| Product Name: | Bendamustine | | Synonyms: | 5-(Bis(2-chloroethyl)amino)-1-methyl-2-benzimidazolebutyric acid;5-[Bis(2-chloroethyl)amino]-1-methyl-1H-benzimidazole-2-butanoic acid;Bendamustine;-1-methyl-1H-benzo[d]imidazol-2-yl);4-(5-(Bis(2-chloroethyl);4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;4-(5-(bis(2-chloroethyl)aMino)-1-Methyl-1H-benzo[d]iMidazol-2-yl)butanoic acid;1H-BenziMidazole-2-butanoicacid, 5-[bis(2-chloroethyl)aMino]-1-Methyl- | | CAS: | 16506-27-7 | | MF: | C16H21Cl2N3O2 | | MW: | 358.26 | | EINECS: | | Product Categories: | | Mol File: | 16506-27-7.mol |
| Bendamustine Chemical Properties |
| Boiling point | 585.2±50.0 °C(Predicted) | | density | 1.31±0.1 g/cm3(Predicted) | | pka | 4.50±0.10(Predicted) |
| Bendamustine Usage And Synthesis |
| Uses | Treatment of
hematologic cancer, especially non-Hodgkin’s lymphoma. | | Brand name | Ribomustine (Amcis AG, Switzerland). | | Enzyme inhibitor | This nitrogen mustard and anticancer drug (FWfree-acid = 358.26 g/mol; CAS 16506-27-7), also known by its code name SDX-105, its trade names Treanda?, Treakisym?, Ribomustin?, and Levact?, as well as by its systematic name 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2- yl]butanoic acid, is a relatively nonspecific DNA alkylating agent that causes intra- and inter-strand cross-links. Bendamustine is used in the treatment of chronic lymphocytic leukemia (CLL), Hodgkin’s disease, nonHodgkin’s lymphoma, multiple myeloma and lung cancer. Pharmacokinetics: After intravenous infusion, >95% of the drug becomes protein-bound, mainly to albumin; however, only free bendamustine is active. Bendamustine is metabolized by liver cytochrome p450, and elimination (renal) is biphasic, with an initial half-life of 6–10 minutes and a terminal half-life of approximately 30 minutes. |
| Bendamustine Preparation Products And Raw materials |
|
日本语
한국어
Français
Deutsch
España
Türkiye